Literature DB >> 8187733

Statistical issues on the no-observed-adverse-effect level in categorical response.

T Yanagawa1, Y Kikuchi, K G Brown.   

Abstract

The determination of the value of the no-observed-adverse-effect level (NOAEL) when observed responses can be categorized by severity (categorical data) and sample sizes are small is discussed. The common situation of only two categories, where only the presence or absence of an effect is observed, is addressed first (dichotomous data). Three tests for dichotomous data are critically examined, including the Brown-La Vange test, a modified version of that test, and Dunnett's multiple comparison test. Although the modified test is an improvement, all three procedures have shortcomings in determining the value of the NOAEL, particularly when the sample size is small. An alternative method is suggested, based on the Akaike information criterion (AIC), which performs well. This method is extended to severity data with an arbitrary number of categories. Use of a dose-response curve for the NOAEL is discussed.

Mesh:

Year:  1994        PMID: 8187733      PMCID: PMC1566885          DOI: 10.1289/ehp.94102s195

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  6 in total

1.  CHRONIC ORAL TOXICITY OF ALDRIN AND DIELDRIN IN RATS AND DOGS.

Authors:  O G FITZHUGH; A A NELSON; M L QUAIFE
Journal:  Food Cosmet Toxicol       Date:  1964-11

2.  A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment.

Authors:  E Shirley
Journal:  Biometrics       Date:  1977-06       Impact factor: 2.571

3.  Statistical uncertainty in the no-observed-adverse-effect level.

Authors:  K G Brown; L S Erdreich
Journal:  Fundam Appl Toxicol       Date:  1989-08

4.  A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control.

Authors:  D A Williams
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

5.  A test for differences between treatment means when several dose levels are compared with a zero dose control.

Authors:  D A Williams
Journal:  Biometrics       Date:  1971-03       Impact factor: 2.571

6.  A new method for determining allowable daily intakes.

Authors:  K S Crump
Journal:  Fundam Appl Toxicol       Date:  1984-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.